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Sir,
Re: Symptomatic asthma: attendance and
prescribing in general practice (Respir Med 96:
102^109): Critique of Nolan andwhite
I applaud Nolan andWhite for their careful and pains-
taking analysis of patients with asthma in primary care
who have high symptom levels (1). This is an important
group to understand as they consume a disproportio-
nately high level of resource (2), and valuable data on
their primary care management are presented. There
are however other interpretations that can be drawn
from these data than the somewhat pessimistic and
nihilistic conclusion of the authors that ‘continuing
symptoms will remain the reality for many patients with
asthma’.
I feel rather that most of these symptomatic patients
remain undertreated. In spite of almost daily symptoms,
one in four patients was not receiving inhaled corticos-
teroids (ICS) at anydosage, and onlyone in10wasreceiv-
ing long-acting B2 agonists. No information is given on
other adjuvant therapies. There is now compelling evi-
dence that the addition of long-acting B2 agonists in pa-
tients who remain symptomatic on low-dose ICS is
extremelye¡ective in improving awidevarietyof asthma
outcomes, including symptoms and exacerbations (3).
The low level of usage in this group of patients who are
symptomatic and have a high requirement for oral ster-
oid courses for exacerbations points to a major area of
undertreatment. In addition, leukotriene receptor an-
tagonists have been shown to be e¡ective as monother-
apy (4) and in addition to ICS (5) in symptomatic patients.
The observed heterogeneity of response to ICS (5, 6)
tells us that treatment with ICS alone cannot be the
yardstick for undertreatment, and persistent symptoms
indicate the need for trials of adjuvant therapy.
In addition, there seem to bemany aspects of the de-
livery of care that could be improved to lead to better
outcomes of care in these patients.One-third of patients
had not been seen for asthma review at all, only one in
six had attended a practice-based asthma clinic, onlyone in four had had their peak £ow recorded and one in
three their inhaler technique documented in the year
prior to the survey. There is compelling evidence that
the provision of written self-management plans improve
outcomes (7), yet less than one in10 had been given one.
This valuable real-world survey of people with persis-
tent asthma symptoms in the community shows that the
pharmacological management and the delivery of care
could indeed be improved.We need to continue our ef-
forts to raise standards of care in the community and to
re¢ne delivery of care to meet the needs of patients.
M.THOMAS
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